Skip to content

Real-World Treatment and Efficacy Analysis of RAS-Mutant Metastatic Colorectal Cancer

Real-World Treatment and Efficacy Analysis of RAS-Mutant Metastatic Colorectal Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500113709
Enrollment
Unknown
Registered
2025-12-02
Start date
2026-01-01
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Interventions

Two-drug chemotherapy group:None.
Three-drug chemotherapy group:None.

Sponsors

Central Hospital of Guangdong Provincial Nongken
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Aged between 18 and 75 years; (2) Histologically or cytologically confirmed diagnosis of colon or rectal cancer; (3) Presence of distant metastases confirmed by CT or MRI, including but not limited to the liver, lungs, peritoneum, ovaries, distant lymph nodes, bone, brain, and adrenal glands; (4) Documented KRAS/NRAS mutation as identified by genetic testing.

Exclusion criteria

Exclusion criteria: (1) Incomplete medical records; (2) Concurrent other primary malignant tumors; (3) Presence of MSI-H identified by genetic testing or dMMR by immunohistochemistry; (4) Pregnancy or lactation; (5) Severe complications or comorbidities, such as severe cardiovascular and cerebrovascular diseases, hepatic or renal insufficiency, etc.

Design outcomes

Primary

MeasureTime frame
Objective Response Rate;

Secondary

MeasureTime frame
Progression-Free Survival;Overall Survival;

Countries

China

Contacts

Public ContactWenfeng Yin

Central Hospital of Guangdong Provincial Nongken

yinwenfengemail@163.com+86 176 7431 3003

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026